• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button Iconweight-loss and diet control industry

weight-loss and diet control industry

Page 5 of 10
Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk
Retail
Denmark’s Novo Nordisk forecasts 27% sales surge but faces price pressure amid Eli Lilly competition
By Naomi Kresge and BloombergMay 2, 2024
New York outlaws sales of diet pills and muscle-mass builders to children
Retail
New York outlaws sales of diet pills and muscle-mass builders to children
By Maysoon Khan and The Associated PressApril 25, 2024
Lars Fruergaard Jorgensen
Health
No evidence Ozempic and Wegovy raise risk of self harm, EU regulators said
By Jonel Aleccia and The Associated PressApril 12, 2024
After testing new drug compounds that appear to mimic the physical benefits of exercise in rodents, scientists say a pill may someday be able to do the same in humans.
Life
An exercise pill may soon offer the same benefits as a workout, scientists say
By Lindsey LeakeMarch 18, 2024
Oprah Winfrey
Finance
WeightWatchers, reeling from collapsing stock and Oprah’s departure in the age of Ozempic, vows to ‘prove the naysayers wrong’ and turn its fortunes around
By Amanda GerutMarch 14, 2024
Catherine Howarth, CEO of ShareAction.
Retail
Rebel investors want KitKat maker Nestlé to cut back on junk food—but the fortunes of its Mindful Chef brand suggest customers aren’t ready for a health kick
By Ryan HoggMarch 14, 2024
A person using Ozempic
Retail
Wegovy and Ozempic have ignited a gold rush in pharma as well as an upsurge in fake ‘skinny jabs’, leading to surge in hospitalizations
By Ashleigh Furlong and BloombergMarch 13, 2024
Does the GOLO Diet work? Experts explain the pros, cons, and risks
Life
Does the GOLO Diet work? Experts explain the pros, cons, and risks
By Amanda LoudinMarch 9, 2024
tube of wegovy injections
Lifestyle
Novo Nordisk eclipses Tesla on positive trial results for a weight loss drug that may be more powerful than its own Wegovy 
By Prarthana PrakashMarch 8, 2024
62-year-old who lost 40 pounds in 9 months on Wegovy wants to stop the treadmill: ‘At some point you have to come off of them. I don’t want to be on them forever’
Health
62-year-old who lost 40 pounds in 9 months on Wegovy wants to stop the treadmill: ‘At some point you have to come off of them. I don’t want to be on them forever’
By Jonel Aleccia and The Associated PressMarch 7, 2024
WHO
Health
A billion people worldwide are obese and Ozempic and other weight-loss drugs aren’t a solution, WHO says
By Naomi Kresge, Angela Feliciano and BloombergMarch 1, 2024
Oprah Winfrey
Leadership
Oprah to leave WeightWatchers board, donating her stake over ‘perceived conflict of interest around her taking weight loss medications’
By Amanda GerutFebruary 28, 2024
BOXES OF WEGOVY DRUGS
Lifestyle
Novo Nordisk faces competition close to home as Danish rival Zealand Pharma’s shares jump 35% on ‘groundbreaking’ weight-loss drug trial results
By Prarthana PrakashFebruary 27, 2024
Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
Retail
Novo Nordisk’s CEO says he’s fielding calls from ‘scared’ junk food suppliers asking for advice over Ozempic surge
By Ryan HoggFebruary 8, 2024
Lars Fruergaard Jorgensen holding flashcards and talking
Retail
Novo Nordisk CEO says he was ‘surprised’ to see the popularity of weight-loss drugs in Europe—and people’s readiness to pay out of pocket for them
By Prarthana PrakashFebruary 5, 2024
1...
  • 3
  • 4
  • 5
  • 6
  • 7
...10
Most Popular
Success
After donating $8 billion, Steve and Connie Ballmer create three regional philanthropies so people closest to the work can decide how the money is spentplaceholder alt text
By Sydney LakeAugust 11, 2026
Economy
U.S. Treasury is paying $3 billion a day in interest on national debt, says the CBO—having spent $10 billion to prop up the currency of its top lenderplaceholder alt text
By Eleanor PringleAugust 11, 2026
North America
Google cofounder Sergey Brin has now spent $100 million to fight California’s proposed billionaire tax—he could owe $13 billion if he losesplaceholder alt text
By Sasha RogelbergAugust 11, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.